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Artemisinin-Based Treatments in Pregnant Women with Malaria
To the Editor: The Pregnancy Artemisinin-
Based Combination Treatments (PREGACT) Study 
Group compared the polymerase-chain-reaction 
(PCR)–adjusted “recrudescence” rates of Plasmo-
dium falciparum infection after treatment and sug-
gest that this indicates the failure to eradicate 
the initial infection (March 10 issue).1 However, 
analysis of the PCR-adjusted and PCR-unadjusted 
survival curves of time to “treatment failure” 
(Fig. S1 in the Supplementary Appendix, avail-
able with the full text of the article at NEJM.org) 
suggests that the curves are equally well ex-
plained by a constant rate of new infections, a 
proportion of which are misclassified as recru-
descent. The percentage of infections classified 
as recrudescent is 9.9% (68 of 686) across the 
cohort (Table 2 of the article) and does not differ 
significantly among the four drug regimens 
(P = 0.64 by the chi-square test). Nor is there evi-
dence of an early clustering of PCR-adjusted in-
fection, as might be expected from treatment 
failure.2,3 In fact, the only significant difference 
between drugs appears to be their duration of 
post-treatment prophylaxis. It is important to 
clarify terminology, because assuming that all 
PCR-adjusted infections indicate failure to eradi-
cate existing parasites may exaggerate estimates 
of the recrudescence rate and therefore of drug 
resistance. Parasite genotyping may perform 
poorly in areas of high transmission,4 and con-
sideration of the underlying infection kinetics 
can provide additional insights.
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The author replies: In our trial, women were 
actively followed for 9 weeks, so it was necessary 
to genotype recurrent infections, to distinguish 
between new infection and recrudescence, the 
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latter considered to be a “true” treatment failure. 
Our main hypothesis was that the four treat-
ments would have similar efficacy, and indeed 
the differences between the PCR-adjusted cure 
rates were within the prespecified equivalence 
margin of 5 percentage points. Genotyping was 
carried out according to standard methods,1 
whose limitations, particularly where transmis-
sion is intense, were mentioned in the Discussion 
section of our article. Adekunle et al. state that 
the recrudescence rate equates to resistance. 
However, it is well known that this is not true, 
because observed therapeutic failure may be due 
to factors other than parasitologic resistance 
(e.g., malabsorption and rapid or abnormal me-
tabolism),2 and this may be particularly true for 
pregnant women.3 We have also stated that there 
are major differences in the duration of the post-
treatment prophylaxis between treatments, and 
this is shown by the PCR-unadjusted cure rates.
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Trimethoprim–Sulfamethoxazole for Uncomplicated  
Skin Abscess
To the Editor: Talan et al. (March 3 issue)1 
slightly misstate the findings of an earlier sum-
mary to which I contributed.2 My fellow authors 
and I concluded that prior studies of antibiotics 
administered in patients with uncomplicated ab-
scesses were underpowered because the authors 
of those studies could not rule out the 5 to 10% 
superiority of antibiotics suggested in our review. 
The current study was well designed to address 
this concern. Comment is also warranted regard-
ing the trial guidance provided by the Food and 
Drug Administration (FDA) on an early end point 
that is required as the primary end point for reg-
istrational studies and was a secondary end point 
in the study by Talan et al. The FDA guidance 
indicates that patients are considered to have 
been treated successfully even if 80% of their in-
fection remains unresolved after 3 days of thera-
py. Space limitations here preclude a thorough 
discussion of this objectionable end point.3 The 
trial by Talan et al. is at least the second random-
ized, controlled trial (RCT) that has shown that 
the early end point does not correlate well with 
test-of-cure success.4 Furthermore, the current 
trial adds to the data that show that an “end-of-
therapy cure” end point is sensitive to the effi-
cacy of the antibiotic for skin infections.5 In my 
opinion, the early end point should be aban-
doned.
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To the Editor: Talan et al. reported higher per-
protocol cure rates for abscesses treated with tri-
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